NeuroStar Advanced Therapy by Neuronetics: status and timeline

Milestones

Next · Full year 2026 revenue target

FDA approval for medication-resistant depression2008Complete.
NeuroStar becomes standard-of-care therapy in US2020Complete.
Dan Reuvers appointed CEO23 Mar 2026Complete.
Greenbrook opens National Center of Excellence in Rockville, MarylandJul 2026Complete.
NeuroStar integrates with EHR/EMR systemsSep 2026Complete.
Full year 2026 revenue targetTarget Dec 2026Current milestone.

Upcoming

Q4 2026EHR integration rollout (next)
Dec 2026Full year 2026 revenue target
2027Greenbrook clinic expansion

Current obstacles

Clinic capacity optimization40% of Greenbrook clinic capacity remains unused; requires improvements in patient qualification.
Competitive pressureCompetition from newer antidepressants, ketamine clinics, and other psychiatric interventions.

Physics limits

Indication limited to treatment-resistant depressionFDA approval covers only patients who failed one antidepressant. Off-label use for other psychiatric conditions exists but lacks FDA sanction.
Patient access barriersRequires multi-week outpatient commitment (4–6 weeks, daily). Insurance coverage variable by payer; out-of-pocket costs limit patient pool.

How it works

3 parts

Technology

Magnetic stimulation

MRI-strength magnetic pulses delivered via coil against scalp stimulate nerve cells in brain regions linked to depression. Requires no anesthesia or sedation.

Mechanism

Neuronal depolarization

Pulses induce neuronal depolarization; exact mechanism unclear, but results in depression relief.

Delivery

Greenbrook clinic network

Administered in Greenbrook outpatient clinics (46 locations Q2 2026, $26.9M revenue, +16.8% YoY).

Spec sheet

Spec	NeuroStar Advanced Therapy
Treatment session	40 minutes^R (reported)
Full course	Daily for 4 to 6 weeks^R (reported)
Clinical response rate	One in two patients show improvement^R (reported)
Depression-free (remission)	One in three patients^R (reported)
FDA indication	Treatment-resistant major depression^R (reported)

^R reported by the company

About Neuronetics

The team behind NeuroStar Advanced Therapy

Neuronetics

TMS, depression treatment, Greenbrook

Medical device company operating NeuroStar TMS systems and Greenbrook psychiatric clinics for depression treatment.

neuronetics.com (opens neuronetics.com)Company profile →

Founded: 200323 yrs
Headquarters: United States
Status: Public
Listed: NASDAQ:STIM
Valuation: public
Works in: NeurotechStimulation therapies
Coverage: 1 program · 0 updateschecked 11 Oct
People: Dan ReuversPresident and CEO